Reig Jofre releases first half 2020 results note

REIG JOFRE invoiced € 115M in the first quarter of 2020, with a growth in sales of 25% and an EBITDA of € 13M, 40% above the 2019 figure. The strong growth rate of 1Q20 is maintained at 26%.

In a context still conditioned by the COVID 19 crisis, sales have tracked the growth rate registered in 1Q20, driven by the incorporation of the new Osteoarticular area, as well as the sales of essential drugs required by the health system.